While most drugs that lower apolipoprotein B (apoB) also reduce cardiovascular events, the absence of a reliable brain biomarker or functional study makes it difficult to assess the long-term benefits of interventions like DHA for dementia prevention.

“but in the absence of such a biomarker or functional study you know it doesn't have to be a biomarker i guess if you had you know an imaging study or a functional study that that you know could matter you know hippocampal volume if that be if we believe that that was sensitive enough but absent that it still comes down to a question of what's the asymmetry of risk on each side right so option one is do nothing option two is either through diet or supplement take a given amount of dha what is the downside of the ladder what is the downside of the former i think those are questions that we have to spend more time thinking about because i don't think that clinical trials can give us answers to some of the most important questions facing disease prevention”